Abstinence Reinforcement Therapy for Veterans Who Smoke Tobacco and Are Experiencing Homelessness (New HART)
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Angela C Kirby, MS
- Número de teléfono: 7456 (919) 286-0411
- Correo electrónico: angela.kirby@va.gov
Ubicaciones de estudio
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27705-3875
- Durham VA Medical Center, Durham, NC
-
Contacto:
- Angela C Kirby, MS
- Número de teléfono: 7456 919-286-0411
- Correo electrónico: angela.kirby@va.gov
-
Investigador principal:
- Jean C Beckham, PhD
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Are homeless
- Smoke at least 5 cigarettes daily with CO indicating current smoking at time of screening assessment
- Are willing to try to quit smoking in next 30 days
Exclusion Criteria:
- Have uncontrolled psychotic symptoms
- Have active substance dependence other than nicotine (participants in partial remission with at least one month sobriety will be included)
- Have severely impaired hearing or speech
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Abstinence Reinforcement Therapy +
Abstinence Reinforcement Therapy +, or ART+, includes five sessions and several booster sessions of cognitive-behavioral therapy for smoking cessation, two forms of nicotine replacement therapy plus bupropion or varenicline, and mobile contingency management for smoking cessation.
|
Five core sessions of CBT plus up to four monthly booster sessions designed to help Veterans prepare to quit smoking, make a quit attempt, and prevent relapse to smoking.
Otros nombres:
NRT is a group of over-the-counter medications designed to help users quit smoking.
Standard of care often involves use of nicotine patch plus one rescue method (either gum or lozenge).
Otros nombres:
Bupropion is an FDA-approved prescription smoking cessation aid.
Participants will be prescribed 150-300 mg.
Otros nombres:
Varenicline is an FDA-approved prescription smoking cessation aid.
Participants will be 0.5 to 2 mg.
Otros nombres:
Smoking abstinence will be intermittently reinforced.
For each carbon monoxide (CO) reading that a participant provides that suggest smoking abstinence, the participant will earn spins on a virtual prize wheel that has financial prizes.
Otros nombres:
|
|
Comparador activo: Standard Care Condition
Standard Care Condition will involve referral to local VA clinic-based smoking cessation care.
This care often includes pharmacotherapy, counseling options, and/or use of a telephone-based, texting-based or app-based smoking cessation program.
|
NRT is a group of over-the-counter medications designed to help users quit smoking.
Standard of care often involves use of nicotine patch plus one rescue method (either gum or lozenge).
Otros nombres:
Bupropion is an FDA-approved prescription smoking cessation aid.
Participants will be prescribed 150-300 mg.
Otros nombres:
Varenicline is an FDA-approved prescription smoking cessation aid.
Participants will be 0.5 to 2 mg.
Otros nombres:
Participants assigned to the usual care condition may participate in group counseling for smoking cessation, which can also include use of phone-based smoking cessation resources such as a telephone quit line, a texting program, and a smoking cessation app.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of participants whose self-report of prolonged smoking abstinence is bioverified
Periodo de tiempo: 6-month follow-up, about six months after baseline
|
Prolonged abstinence is defined as 30 days abstinent.
For participants who are not using NRT/vapes/e-cigarettes at follow-up, abstinence will be based upon: 1) self-reported abstinence; 2) no biochemical samples indicating smoking (CO ≥ 5 ppm or cotinine ≥ 6 ng/mL); and 3) at least one sample indicating abstinence (CO < 5 ppm and/or cotinine < 6 ng/mL)
|
6-month follow-up, about six months after baseline
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of participants whose self-report of prolonged smoking abstinence is bioverified
Periodo de tiempo: 3-month follow-up, about three months after baseline
|
Prolonged abstinence is defined as 30 days abstinent.
For participants who are not using NRT/vapes/e-cigarettes at follow-up, abstinence will be based upon: 1) self-reported abstinence; 2) no biochemical samples indicating smoking (CO ≥ 5 ppm or cotinine ≥ 6 ng/mL); and 3) at least one sample indicating abstinence (CO < 5 ppm and/or cotinine < 6 ng/mL)
|
3-month follow-up, about three months after baseline
|
|
Number of participants whose self-report of prolonged smoking abstinence is bioverified
Periodo de tiempo: 12-month follow-up, about twelve months after baseline
|
Prolonged abstinence is defined as 30 days abstinent.
For participants who are not using NRT/vapes/e-cigarettes at follow-up, abstinence will be based upon: 1) self-reported abstinence; 2) no biochemical samples indicating smoking (CO ≥ 5 ppm or cotinine ≥ 6 ng/mL); and 3) at least one sample indicating abstinence (CO < 5 ppm and/or cotinine < 6 ng/mL
|
12-month follow-up, about twelve months after baseline
|
|
Number of participants who self-report 7-day point prevalence abstinence
Periodo de tiempo: 3-month follow-up, about three months after baseline
|
7-day point prevalence abstinence is defined as no smoking in the prior 7 days
|
3-month follow-up, about three months after baseline
|
|
Number of participants who self-report 7-day point prevalence abstinence
Periodo de tiempo: 6-month follow-up, about six months after baseline
|
7-day point prevalence abstinence is defined as no smoking in the prior 7 days
|
6-month follow-up, about six months after baseline
|
|
Number of participants who self-report 7-day point prevalence abstinence
Periodo de tiempo: 12-month follow-up, about twelve months after baseline
|
7-day point prevalence abstinence is defined as no smoking in the prior 7 days
|
12-month follow-up, about twelve months after baseline
|
|
Number of participants who self-report 30-day point prevalence abstinence
Periodo de tiempo: 3-month follow-up, about three months after baseline
|
7-day point prevalence abstinence is defined as no smoking in the prior 30 days
|
3-month follow-up, about three months after baseline
|
|
Number of participants who self-report 30-day point prevalence abstinence
Periodo de tiempo: 6-month follow-up, about six months after baseline
|
7-day point prevalence abstinence is defined as no smoking in the prior 30 days
|
6-month follow-up, about six months after baseline
|
|
Number of participants who self-report 30-day point prevalence abstinence
Periodo de tiempo: 12-month follow-up, about twelve months after baseline
|
30-day point prevalence abstinence is defined as no smoking in the prior 30 days
|
12-month follow-up, about twelve months after baseline
|
|
Number of participants who self-report early continuous abstinence
Periodo de tiempo: 3-month follow-up, about three months after baseline
|
Early continuous abstinence will be defined as reporting two weeks of continuous abstinence during the first four weeks after the quit day
|
3-month follow-up, about three months after baseline
|
|
Incremental Cost-Effectiveness Ratio
Periodo de tiempo: 12 months post quit, about 12 months after baseline
|
Measure of cost-effectiveness; costs as the numerator and effectiveness as measured by quality-adjusted life years (QALY) as the denominator.
|
12 months post quit, about 12 months after baseline
|
|
Percentage of carbon monoxide reading completion by participants in ART+ intervention group
Periodo de tiempo: 3-month follow-up, about three months after baseline
|
Patient intervention utilization will be measured by the percentage of prompted carbon monoxide readings that participants in the ART+ condition complete during the treatment period.
|
3-month follow-up, about three months after baseline
|
|
Number of behavioral cognitive-behavioral therapy (CBT) sessions completed by participants in ART+ intervention group
Periodo de tiempo: 3-month follow-up, about three months after baseline
|
Patient intervention utilization will be measured by the number of behavioral cognitive-behavioral therapy (CBT) sessions completed by participants in the ART+ condition during the treatment period
|
3-month follow-up, about three months after baseline
|
|
Number of participants in ART+ intervention group who withdraw or are lost to contact during the treatment period
Periodo de tiempo: 3-month follow-up, about three months after baseline
|
Patient intervention utilization will be measured by the number of participants in ART+ intervention group who withdraw or are lost to contact during the treatment period.
|
3-month follow-up, about three months after baseline
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Jean C Beckham, PhD, Durham VA Medical Center, Durham, NC
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Desordenes mentales
- Trastornos relacionados con sustancias
- Trastornos inducidos químicamente
- Comportamiento
- Trastorno por consumo de tabaco
- De fumar
- Químicos orgánicos
- Piridina
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Terapéutica
- Terapia con drogas
- Alimento
- Dieta, alimentos y nutrición
- Fenómeno fisiológico
- Comida y bebidas
- Carbohidratos
- Alcaloides
- Terapia conductual
- Psicoterapia
- Disciplinas y actividades de comportamiento
- Polímeros
- Sustancias macromoleculares
- Polisacáridos
- Benzazepines
- Cetonas
- Biopolímeros
- Quinoxalinas
- Encías vegetales
- Dulce
- Alcaloides solanáceos
- Goma de mascar
- Propiofenones
- Vareniclina
- Nicotina
- Bupropión
- Terapia cognitiva conductual
- Tobacco Use dispositivos de cesación
- Terapia de reemplazo de nicotina
- Chicle de nicotina
Otros números de identificación del estudio
Otros números de identificación del estudio
- HSR2-003-25M
- 1924743 (Otro identificador: Durham VA Medical Center IRB)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .